Search for European Projects

34 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Start date: Jun 1, 2015, End date: Nov 30, 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Read Project

 25

 FINISHED 

Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines (PEARRL)

Start date: May 1, 2016, End date: Apr 30, 2020,

The European Pharma industry is a major contributor to EU well-being, both in public health and economic (sales >200 billion €/year) terms. To maintain global leadership, it must respond to challenges from low-cost producers e.g. China by bringing new drug molecules to market in a streamlined, cost-effective manner. This strategy is underscored by recent initiatives of European regulators to exped ...
Read Project

 9

 FINISHED 

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes (DiViNe)

Start date: Mar 1, 2015, End date: Feb 29, 2020,

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations ...
Read Project

 6

 FINISHED 

Development of high-performance, hyperfluorescence OLEDs for use in display applications and solid state lighting (HyperOLED)

Start date: Jan 1, 2017, End date: Dec 31, 2019,

The overall goal of the HyperOLED project is to develop materials and matching device architectures for high-performance, hyperfluorescence organic light emitting diodes (OLEDs) for use in display applications and solid state lighting. The innovative OLEDs will be realised by combining thermally activated delayed fluorescence (TADF) molecular hosts with novel shielded fluorescence emitters, target ...
Read Project

 5

 FINISHED 

Production technology to achieve low Cost and Highly Efficient phOtovoltaic Perovskite Solar cells (CHEOPS)

Start date: Feb 1, 2016, End date: Jan 31, 2019,

The aim of CHEOPS is to develop very low-cost but highly performing photovoltaic (PV) devices based on the emerging perovskite (PK) technology. At lab scale (20%. But only few attempts at upscaling have been made, yielding significantly reduced efficiencies 14% stable for aperture area in modules >15x15cm2). This will demonstrate the potential of PK as a very low-cost technology (target 29% on 2x2 ...
Read Project

 13

 FINISHED 

Advanced high-resolution printing of organic Transistors for Large Area Smart Surfaces (ATLASS)

Start date: Mar 1, 2015, End date: Aug 31, 2018,

Bringing intelligence and communication to everyday objects is a major challenge for future electronics. This « Internet of Things » concept envisions wide dissemination with new performances: robustness, large area, flexibility, eco-efficient large volume manufacturing at low cost. Beyond current TOLAE demonstration, a major technology jump driving the scalability towards nanoscale resolution via ...
Read Project

 17

 FINISHED 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Start date: Sep 1, 2011, End date: Dec 31, 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Read Project

 26

 FINISHED 

European Medical Information Framework (EMIF)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Read Project

 64

 FINISHED 

European Lead Factory (EUC²LID)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Read Project

 34

 FINISHED 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Read Project

 21

 FINISHED 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Read Project

 17

 FINISHED 

Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Start date: Oct 1, 2012, End date: Sep 30, 2017,

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a we ...
Read Project

 38

 FINISHED 

BeTheCuRE (BTCURE)

Start date: Apr 1, 2011, End date: Mar 31, 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Read Project

 41

 FINISHED 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Start date: Mar 1, 2012, End date: Feb 28, 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Read Project

 39

 FINISHED 

European Patients' Academy on Therapeutic Innovation (EUPATI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

"The proposed project ""European Patients' Academy on Therapeutic Innovation"" (EUPATI) contributes to IMI’s goal of raising patients’ awareness and participation in pharmaceutical R&D. This patient-led academy will provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical R&D. It will increase the capacity of well-informed patients to be effective advocat ...
Read Project

 33

 FINISHED 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 

Incorporating real-life clinical data into drug development (GETREAL)

Start date: Oct 1, 2013, End date: Dec 31, 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Read Project

 32

 FINISHED 

OncoTrack - Methods for systematic next generation oncology biomarker development (ONCOTRACK)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same p ...
Read Project

 22

 FINISHED 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Start date: Jan 1, 2010, End date: Nov 30, 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Read Project

 34

 FINISHED 

OFET biosensors for point-of-care applications (sense-of-care)

Start date: Dec 1, 2012, End date: Nov 30, 2016,

Electronic, label-free biosensors characterized by rapidity and detection proved to be very promising being able to directly detect biological recognition events without the need of markers. In this respect, organic bioelectronics has gained a huge interest among scientists coming from different disciplines and sectors due to its high impact on medical, clinical, food and environmental fields. Pre ...
Read Project

 3

 FINISHED 

Drug Disease Model Resources (DDMORE)

Start date: Mar 1, 2011, End date: Aug 31, 2016,

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Read Project

 28

 FINISHED 

Electronic Health Record systems for Clinical Research (EHR4CR)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Read Project

 37

 FINISHED 

The Open Pharmacological Concepts Triple Store (OPEN PHACTS)

Start date: Mar 1, 2011, End date: Feb 29, 2016,

Drug discovery is data-hungry and all major pharmaceutical companies maintain extensive in-house instances of public data alongside internal. Analysis and hypothesis generation for drug-discovery projects requires assembly, overlay and comparison of data from many sources, requiring shared identifiers and common semantics. Expression profiles need to be overlaid with gene or pathway identifiers an ...
Read Project

 32

 FINISHED 

Integrated In Silico Models for the Prediction of Human Repeated Dose Toxicity of Cosmetics to Optimise Safety (COSMOS)

Start date: Jan 1, 2011, End date: Dec 31, 2015,

The COSMOS project will address the assessment needs of the cosmetics industry by delivering an integrated suite of computational tools to predict the effects of long-term exposure to cosmetic ingredients in humans, thus reducing the need for repeated dose toxicity testing in animals. To achieve this, individual modules comprising: (new) databases, thresholds of toxicological concern (TTC), in sil ...
Read Project

 15

 FINISHED 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Start date: Jan 1, 2010, End date: Dec 31, 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Read Project

 38

 FINISHED 

DEVELOPMENT OF NEW UV LASER FOR CUSTOMIZATION AT INDUSTRIAL LEVEL THROUGH HIGH QUALITY MARKING ON DIFFERNT MATERIALS (UV-Marking)

Start date: Jul 1, 2012, End date: Oct 31, 2015,

...ID will work in the field of glass and ceramic materials. Finally, 3 different groups of ICMA (from University of Zaragoza and CSIC) will participate as experts on laser and materials.The company Merck has also contributed to UV-Marking during the first months of the project, before the incorporation of DATALASE.
Read Project

 12

 FINISHED 

Development and scale-up of nanostructured based materials and processes for low cost high efficiency chalcogenide based photovoltaics (SCALENANO)

Start date: Feb 1, 2012, End date: Jul 31, 2015,

This project will exploit the potential of chalcogenide based thin film photovoltaic technologies for the development and scale-up of new processes based on nanostructured materials for the production of high efficiency and low cost photovoltaic devices and modules compatible with mass production requirements. Cu(In,Ga)(S,Se)2 (CIGS) chalcogenide based devices have the highest efficiency of all th ...
Read Project

 14

 FINISHED 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Start date: Sep 1, 2009, End date: Apr 30, 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Read Project

 36

 FINISHED 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Start date: May 1, 2009, End date: Apr 30, 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Read Project

 52

 FINISHED 

EUROpean multilevel integrated BIOREFinery design for sustainable biomass processing (EuroBioRef)

Start date: Mar 1, 2010, End date: Feb 28, 2014,

The development and implementation of bio-refinery processes is an absolute necessity and the key to meet the vision towards bio-based economy. The EuroBioRef concept is an integrated, sustainable and diversified bio-refinery involving all biomass value chain stakeholders. The latter will allow large-scale research, testing, optimisation and demonstration of processes in the production of a wide r ...
Read Project

 34

 FINISHED 

Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics (Predict-IV)

Start date: May 1, 2008, End date: Oct 31, 2013,

The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early develo ...
Read Project

 20

 FINISHED 

Advanced Magnetic nanoparticles deliver smart Processes and Products for Life (MagPro²Life)

Start date: Jul 1, 2009, End date: Jun 30, 2013,

Biotechnologically derived substances for large scale feed, food and pharma applications represent one of the most important sources of new products due to their precisely controlled structural and functional properties, potential for economic and responsible production and overall broad benefits to society through biocompatibility and sustainability. The costs of producing biomaterials are in man ...
Read Project

 16

 FINISHED 

Organic Nanomaterials for Electronics and Photonics: Design, Synthesis, Characterization, Processing, Fabrication and Applications (ONE-P)

Start date: Jan 1, 2009, End date: Dec 31, 2011,

The call 4.2.2-1 “organic materials for electronics and photonics” is based on the observation that the limited availability of high-performance multi-functional materials is a roadblock to further industrial progress. To address the wide scope of the call, we have identified specific materials bottlenecks to the fields of electronics and photonics. They constitute the focal points of our project. ...
Read Project

 31